Abstract: A fiber splice cassette includes a main chassis, a removable cover, splice sleeve holders, and four cable clamp boots. The main chassis forms a cavity having a plurality of cable organizing tabs for cable management. Splice sleeve holders are located in the cavity of the main chassis, each of the splice sleeve holders being selectively removable from a corresponding splice sleeve holder nest and being configured for specific splicing capabilities while maintaining the structural strength of the holders. The splice sleeve holder nests may be selectively and removably attached to an interior surface of the fiber cable enclosure via a variety of means to allow the splice sleeve holder nests to be easily rotated, relocated, or accessed for maintenance.

Abstract: A method for coherent multidimensional spectroscopy may comprise illuminating a location in a sample with a set of m coherent light pulses, each coherent light pulse having an initial frequency ?m and an initial wave vector {right arrow over (k)}m, wherein m?2, to generate a coherent output signal having an initial frequency ?output=?±?m and an initial wavevector wave vector {right arrow over (k)}output=?±{right arrow over (k)}m; scanning a first coherent light pulse of the set of m coherent light pulses across a set of i frequency values, wherein i?2, the set of i frequency values including the first coherent light pulse having initial frequency ?1; scanning, simultaneously, a second coherent light pulse of the set of m coherent light pulses across a set of i correlated frequency values, the set of i correlated frequency values including the second coherent light pulse having initial frequency ?2, wherein each correlated frequency value is associated with a corresponding frequency value of the set of i frequ

Abstract: A method for coherent multidimensional spectroscopy may comprise illuminating a location in a sample with a set of m coherent light pulses, each coherent light pulse having an initial frequency ?m and an initial wave vector {right arrow over (k)}m, wherein m?2, to generate a coherent output signal having an initial frequency ?output=?±?m and an initial wavevector wave vector {right arrow over (k)}output=?±{right arrow over (k)}m; scanning a first coherent light pulse of the set of m coherent light pulses across a set of i frequency values, wherein i?2, the set of i frequency values including the first coherent light pulse having initial frequency ?1; scanning, simultaneously, a second coherent light pulse of the set of m coherent light pulses across a set of i correlated frequency values, the set of i correlated frequency values including the second coherent light pulse having initial frequency ?2, wherein each correlated frequency value is associated with a corresponding frequency value of the set of i frequ

Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.

Abstract: A fiber splice cassette includes a main chassis, a removable cover, splice sleeve holders, and four cable clamp boots. The main chassis forms a cavity having a plurality of cable organizing tabs for cable management. Splice sleeve holders are located in the cavity of the main chassis, each of the splice sleeve holders being selectively removable from a corresponding splice sleeve holder nest and being configured for specific splicing capabilities while maintaining the structural strength of the holders. The splice sleeve holder nests may be selectively and removably attached to an interior surface of the fiber cable enclosure via a variety of means to allow the splice sleeve holder nests to be easily rotated, relocated, or accessed for maintenance.

Abstract: A method and apparatus includes a substrate, a foam that is applied to the substrate to form a least a portion of an interior trim part, at least one holder fixed to the substrate, and at least one reinforcement member supported by the at least one holder such that, when the foam is applied, the at least one reinforcement member is suspended within the foam.

Abstract: Methods for pump-probe spectroscopy are provided. In an embodiment, such a method comprises directing pump light having a frequency ?pump at a location in a sample to excite a transition between two quantum states of a target entity in the sample, directing probe light at the location to generate a coherent output signal having a frequency ?output and a wavevector koutput, and detecting the output signal as the probe light is scanned over a range of frequencies. In the method, either the transition excited by the pump light is a multiphoton transition corresponding to a frequency difference of n*?pump, wherein n?2; or the probe light is a set of m coherent light pulses, each coherent light pulse having a frequency ?m and a wavevector km, wherein m?2; or both. Systems for carrying out the methods are also provided.

Abstract: A method and apparatus includes a substrate, a foam that is applied to the substrate to form a least a portion of an interior trim part, at least one holder fixed to the substrate, and at least one reinforcement member supported by the at least one holder such that, when the foam is applied, the at least one reinforcement member is suspended within the foam.

Abstract: The invention is directed to sustained release formulations containing oxycodone or a pharmaceutically acceptable salt thereof which provide a mean C24/Cmax oxycodone ratio of 0.6 to 1.0 or 0.7 to 1 after oral administration at steady state to patients and methods thereof.

Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.

Abstract: Oral dosage forms containing an opioid antagonist in a sequestered form are described. The opioid antagonist is sequestered such that it is not released or substantially not released in the gastrointestinal tract from the dosage form which is administered orally intact. However, when the dosage form is chewed, crushed, heated or dissolved in a solvent, and then administered orally, intranasally, parenterally or sublingually, the opioid antagonist is released and at least partially blocks effects of the opioid agonist.

Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.

Abstract: Methods for pump-probe spectroscopy are provided. In an embodiment, such a method comprises directing pump light having a frequency ?pump at a location in a sample to excite a transition between two quantum states of a target entity in the sample, directing probe light at the location to generate a coherent output signal having a frequency ?output and a wavevector koutput, and detecting the output signal as the probe light is scanned over a range of frequencies. In the method, either the transition excited by the pump light is a multiphoton transition corresponding to a frequency difference of n*?pump, wherein n?2; or the probe light is a set of m coherent light pulses, each coherent light pulse having a frequency ?m and a wavevector km, wherein m?2; or both. Systems for carrying out the methods are also provided.

Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.

Abstract: Oral dosage forms containing an opioid antagonist in a sequestered form are described. The opioid antagonist is sequestered such that it is not released or substantially not released in the gastrointestinal tract from the dosage form which is administered orally intact. However, when the dosage form is chewed, crushed, heated or dissolved in a solvent, and then administered orally, intranasally, parenterally or sublingually, the opioid antagonist is released and at least partially blocks effects of the opioid agonist.

Abstract: Oral dosage forms containing an opioid antagonist in a sequestered form are described. The opioid antagonist is sequestered such that it is not released or substantially not released in the gastrointestinal tract from the dosage form which is administered orally intact. However, when the dosage form is chewed, crushed, heated or dissolved in a solvent, and then administered orally, intranasally, parenterally or sublingually, the opioid antagonist is released and at least partially blocks effects of the opioid agonist.

Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.

Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.

Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.

Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.